Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume 9, Issue 9, Pages 1021-1029
Publisher
Elsevier BV
Online
2021-07-22
DOI
10.1016/s2213-2600(21)00134-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
- (2020) Wen-Zhao Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
- (2019) Wenjie Tang et al. LUNG CANCER
- A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
- (2019) Hua Cheng et al. LUNG CANCER
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
- (2018) Wen-Zhao Zhong et al. LANCET ONCOLOGY
- Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
- (2018) Dongsheng Yue et al. Lancet Respiratory Medicine
- The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
- (2018) Song-Tao Xu et al. Journal of Thoracic Oncology
- Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients
- (2017) T Wang et al. INDIAN JOURNAL OF CANCER
- EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
- (2017) Baohui Han et al. LUNG CANCER
- Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients
- (2017) T Wang et al. INDIAN JOURNAL OF CANCER
- Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)
- (2016) Michael Kreuter et al. Journal of Thoracic Oncology
- Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
- (2016) Shuyang Yao et al. Thoracic Cancer
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
- (2015) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
- (2015) Xingsheng Hu et al. PLoS One
- A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
- (2014) Xingsheng Hu et al. LUNG CANCER
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- (2013) Yuankai Shi et al. LANCET ONCOLOGY
- A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
- (2013) Chao Lv et al. World Journal of Surgical Oncology
- Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
- (2012) M. Kreuter et al. ANNALS OF ONCOLOGY
- Adjuvant chemotherapy for surgically resected non–small cell lung cancer
- (2012) Stephanie Heon et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
- (2010) Jean-Yves Douillard et al. Journal of Thoracic Oncology
- Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
- (2010) Qiong Zhao et al. LUNG CANCER
- Staging of non-small cell lung cancer (NSCLC): A review
- (2010) S. Tsim et al. RESPIRATORY MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started